Ra Capital Management, L.P. Ascendis Pharma A/S Transaction History
Ra Capital Management, L.P.
- $4.82 Billion
- Q1 2025
A detailed history of Ra Capital Management, L.P. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Ra Capital Management, L.P. holds 10,281,496 shares of ASND stock, worth $1.62 Billion. This represents 33.28% of its overall portfolio holdings.
Number of Shares
10,281,496
Previous 10,112,744
1.67%
Holding current value
$1.62 Billion
Previous $1.39 Billion
15.1%
% of portfolio
33.28%
Previous 22.55%
Shares
20 transactions
Others Institutions Holding ASND
# of Institutions
270Shares Held
61.9MCall Options Held
151KPut Options Held
226K-
Westfield Capital Management CO LP Boston, MA5.48MShares$862 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$821 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$706 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$669 Million1.14% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.05MShares$480 Million0.31% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.78B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...